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Power Output Is Increased After Phosphorylation of
Myofibrillar Proteins in Rat Skinned Cardiac Myocytes
Todd J. Herron, F. Steven Korte, Kerry S. McDonald
Abstract—-Adrenergic stimulation increases stroke volume in mammalian hearts as a result of protein kinase A
(PKA)-induced phosphorylation of several myocyte proteins. This study investigated whether PKA-induced phosphor-
ylation of myofibrillar proteins directly affects myocyte contractility. To test this possibility, we compared isometric
force, loaded shortening velocity, and power output in skinned rat cardiac myocytes before and after treatment with the
catalytic subunit of PKA. Consistent with previous studies, PKA increased phosphorylation levels of myosin binding
protein C and troponin I, and reduced Ca2 sensitivity of force. PKA also significantly increased both maximal force
(25.48.3 versus 31.611.3 N [P0.001, n12]) and peak absolute power output (2.481.33 versus 3.381.52
W/mg [P0.05, n5]) during maximal Ca2 activations. Furthermore, PKA elevated power output at nearly all loads
even after normalizing for the increase in force. After PKA treatment, peak normalized power output increased 20%
during maximal Ca2 activations (n5) and 33% during half-maximal Ca2 activations (n9). These results indicate
that PKA-induced phosphorylation of myofibrillar proteins increases the power output–generating capacity of skinned
cardiac myocytes, in part, by speeding the step(s) in the crossbridge cycle that limit loaded shortening rates, and these
changes likely contribute to greater contractility in hearts after -adrenergic stimulation. (Circ Res. 2001;89:1184-
1190.)
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Myocardial performance is enhanced when -adrenergicreceptors are stimulated by catecholamines. After
-adrenergic receptor stimulation, myocardial performance is
associated with increased force development and faster rates
of both the rise and fall of force.1 These positive inotropic and
lusitropic effects are mediated by 3-5 cAMP-dependent
protein kinase (protein kinase A [PKA]), which phosphory-
lates several proteins inside cardiac myocytes including the
sarcolemmal Ca2 channel, the ryanodine receptor,2 phospho-
lamban, troponin I (TnI), and myosin binding protein C
(MyBP-C).3 Four of these phosphoproteins (the sarcolemmal
Ca2 channel, ryanodine receptor, phospholamban, and TnI)
are involved with the handling of intracellular Ca2, and the
phosphorylation state of these proteins regulates both the
amplitude and duration of the Ca2 transient. Therefore, it is
generally accepted that Ca2 handling is an important molec-
ular mechanism underlying the inotropic effects of
-adrenergic receptor stimulation.4,5 However, changes in
Ca2 handling may not be the sole mechanism responsible for
the inotropic effects of -adrenergic receptor stimulation,
given that the rise and fall of the Ca2 transient and the
binding of Ca2 to troponin C all appear to be too rapid to
limit the rise and fall of pressure during a heartbeat.6 Thus,
the factors that determine the rise and fall of pressure during
a heartbeat also likely reside, at least in part, within the
myofibrillar proteins.
Phosphorylation of myofibrillar proteins (ie, MyBP-C and
TnI) by PKA may mediate inotropic effects of -adrenergic
stimulation by a mechanism independent of changes in
intracellular Ca2 handling, such as by directly modulating
the rate of crossbridge cycling. However, variable responses
in crossbridge cycling rates have been observed after
-adrenergic stimulation of myocardial preparations. The
-adrenergic receptor agonist isoproterenol was found to
increase the frequency for minimum stiffness in papillary
muscles during isometric barium contractures; this was inter-
preted to reflect an increase in isometric crossbridge cycling
rates.7,8 On the other hand, myofibrillar ATPase activity was
unaltered during Ca2-induced isometric contractions after
PKA treatment of skinned cardiac trabeculae,9 suggesting that
-adrenergic stimulation may not alter overall crossbridge
cycling kinetics during isometric contractions. Variable re-
sults have also been reported from studies that examined the
effect of -adrenergic stimulation on the unloaded shortening
velocity (Vo) of myocardial preparations. Isoproterenol did
not speed Vo of sarcomere shortening at optimal [Ca2]o in
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intact rat cardiac trabeculae preparations.10 In addition, PKA
has been reported to have no effect on Vo in either skinned
cardiac trabeculae11 or single cardiac myocyte preparations12
during maximal Ca2 activations. Contrary to these results,
PKA has been observed to speed Vo in single skinned cardiac
myocytes.13,14 We did not attempt to resolve these discordant
results on isometric properties and unloaded shortening ve-
locities, but rather we studied the effect of PKA on cross-
bridge cycling rates during loaded contractions, which mim-
ics the way myocytes function during the ejection phase of
the cardiac cycle.
Thus, the purpose of this study was to determine whether
PKA-induced phosphorylation of myofibrillar proteins alters
loaded shortening velocity and power output of single
skinned cardiac myocytes. To this end, loaded shortening
velocities and power output were measured in single perme-
abilized rat cardiac myocytes before and after treatment with
the catalytic subunit of PKA.
Materials and Methods
Cardiac Myocyte Preparation
Cardiac myocyte preparations were obtained by mechanical disrup-
tion of hearts from male 2- to 3-month-old Sprague-Dawley rats as
described previously.15 Rats were obtained from Harlan Tekland
(Madison, Wis) and all animal usage was performed according to
guidelines established by the Animal Care and Use Committee of the
University of Missouri. Dimensions of the myocyte preparations are
listed in Table 1. Rats were housed in groups of 2 or 3 and were
provided access to food and propranolol (1 mg/mL)-treated water ad
libitum. Propranolol is a -adrenergic antagonist and was adminis-
tered in an attempt to normalize baseline PKA-induced phosphory-
lation levels of myofibrillar proteins in each animal. The experimen-
tal apparatus for physiological measurements on myocyte
preparations was similar to one previously described in detail.15,16
Compositions of relaxing and activating solutions were as follows
(in mmol/L): EGTA 7, free Mg2 1, imidazole 20, MgATP 4, and
creatine phosphate 14.5 (pH 7.0); various Ca2 concentrations
between 109 (relaxing solution) and 104.5 mol/L (maximal Ca2
activating solution); and sufficient KCl to adjust ionic strength to
180 mmol/L.15 All chemicals were of the highest purity available and
obtained from Sigma.
Force-Velocity and Power-Load Measurements
All mechanical measurements were made at 131°C. The protocol
for force-velocity and power-load measurements has been previously
described in detail.17 Force-velocity and power-load measurements
were made on each myocyte before and after treatment with the
catalytic subunit of bovine PKA (3 to 5 g/mL). First, the myocyte
was transferred into maximal Ca2 activating solution, and once
steady-state force was attained, a series of force clamps was
performed to determine isotonic shortening velocities. Using a servo
system, force was maintained constant for a designated period of
time (150 to 250 ms) while the length change was continuously
monitored. After the force clamp, the myocyte preparation was
slackened to reduce force to near zero to allow estimation of the
relative load sustained during isotonic shortening; the myocyte was
subsequently re-extended to its initial length. An example of a series
of force clamps is shown in Figure 1. After the first series of force
clamps, the myocyte was treated with the catalytic subunit of PKA
for 45 minutes and loaded shortening velocities were again mea-
sured. Force-velocity relationships were also obtained before and
after PKA treatment in a separate group of myocytes during
half-maximal Ca2 activations. A third group of force-velocity
relationships were obtained during half-maximal Ca2 activations
before and after incubation of myocytes with PKA plus bovine
protein kinase inhibitor (PKI, 300 g/mL) to test the specificity of
post-PKA responses.
Data Analysis
Myocyte preparation length traces, force-velocity curves, and power-
load curves were analyzed as previously described.18 Paired t tests
were used to determine whether there were significant differences in
force-velocity parameters before and after PKA treatment.
SDS-PAGE and Autoradiography
To determine myofibrillar substrates of PKA, myofibrillar samples
were incubated with the catalytic subunit of PKA in the presence of
radiolabeled ATP, separated by SDS-PAGE, and visualized by
autoradiography. Briefly, skinned cardiac myocytes (100 g) were
incubated with the catalytic subunit of PKA (3 to 5 g/mL) and 50
Ci [-32P]ATP for 30 minutes. The reaction was stopped by the
addition of electrophoresis sample buffer and heating at 95°C for 3
minutes. The samples were then separated by SDS-PAGE, silver
stained, dried, and subsequently exposed to x-ray film for 1 hour
at 70°C. Figure 2 demonstrates that two myofibrillar proteins
(MyBP-C and TnI) were phosphorylated by PKA, and the apparent
level of baseline phosphorylation of these two proteins was reduced
at the time of euthanasia in animals given the oral -blocker
propranolol (lane 2).
Results
The effects of PKA on myocyte force, shortening velocity,
and power output are summarized in Table 2 and Figure 3.
After PKA treatment, skinned myocytes generated 25%
more force during maximal Ca2 activation (ie, pCa 4.5). The
TABLE 1. Summary of Myocyte Dimensions
Length, m Width, m
Sarcomere Length
pCa 9.0, m pCa 4.5, m
15354 214 2.290.08 2.240.05
Values are meanSD; n12.
Figure 1. Length traces (top) during a series of force clamps
imposed on a single myocyte preparation during maximal Ca2
activation. Velocity of shortening during each load clamp was
taken at the onset of force clamp as described in Materials and
Methods. Length traces labeled a, b, and c correspond to force
clamps a, b, and c.
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top panel of Figure 3 shows that PKA shifted the absolute
force-velocity curves upward, such that the mean velocity of
shortening is greater at each given absolute load. For exam-
ple, before PKA treatment, velocity of shortening was 48
m/s (0.31 muscle length (ML)/s when the absolute load
was 1 N, but after PKA treatment, velocity of shortening
increased to 71 m/s (0.46 ML/s) at the same absolute
load. Based on force-velocity curves, maximum velocity of
shortening (Vmax) increased 51% in response to PKA (for
control, 0.990.27 ML/s; for PKA, 1.490.35 ML/s
[P0.05]) and mean shortening velocity at loads optimal for
power output (Vopt) was 37% faster after PKA treatment (for
control, 0.270.05; for PKA, 0.370.06 ML/s [P0.05])
(Table 2). The bottom panel of Figure 3 shows the effect of
PKA treatment on absolute power-load curves. PKA treat-
ment increased the power output–generating capacity at each
absolute load less than isometric. PKA increased peak abso-
lute power output by 34% during maximal Ca2 activation
(for control, 7022 pW; for PKA, 9419 pW [P0.05]).
The increased peak absolute power output after PKA
treatment may be attributed to greater force-generating ca-
pacity, so that a given load became a lesser relative load,
which allowed the myocyte to shorten faster in accordance
with the force-velocity relationship. Alternatively, PKA-
induced phosphorylation of myofibrillar proteins may have
directly sped loaded crossbridge cycling rates, such that
velocity of shortening was faster at the same relative load. To
Figure 3. Summary of effects of PKA on force-velocity and
absolute power-load curves in cardiac myocyte preparation
(n5) during maximal Ca2 activations. After PKA treatment,
there was an increase in both maximal force and power output.
The increase in force in this figure underestimates the actual
increase in force when measured directly (see values in Tables 2
and 3). Bars indicate SEs for both force (horizontal bars) and
power output (vertical bars).
TABLE 2. PKA Effects on Maximal Ca2 Activated Force,
Velocity, and Peak Power Output
Before PKA After PKA
Maximum force, N 7.01.8 8.61.7*
Maximum force, kN  m2 29.77.3 37.510.1*
Vmax, ML  s1 0.990.27 1.490.35*
Vopt, ML  s1 0.270.05 0.370.06*
Fopt 0.280.03 0.250.03
Peak absolute power output, pW 70.321.7 94.219.3*
Peak power output, W  mg1 2.481.33 3.381.52*
Peak normalized power output,
P/Po  ML  s1
0.0770.006 0.0920.014*
Values are meanSD; n5. Fopt indicates relative force at which power was
optimal. *Significant difference from before PKA; P0.05.
TABLE 3. PKA Effects on Half-Maximal Ca2 Activated Force,
Velocity, and Peak Power Output
Before PKA After PKA
Maximum force, N 8.29.7 10.05.62*
Maximum force, kN  m2 22.27.5 27.210.0*
Vmax, ML  s1 0.500.13 0.610.11*
Vopt, ML  s1 0.170.04 0.220.03*
Fopt 0.340.04 0.360.05
Peak absolute power output, pW 41.439.7 67.247.5*
Peak power output, W  mg1 0.720.35 1.170.45*
Peak normalized power output,
P/Po  ML  s1
0.0570.016 0.0760.014*
Values are meanSD; n9. *Significant difference from before PKA;
P0.05.
Figure 2. Autoradiogram showing phosphate incorporation into
MyBP-C and cardiac TnI after PKA treatment in skinned cardiac
myocytes. Lane 1 contains skinned cardiac myocytes (17 g)
obtained from a control rat, whereas lane 2 contains myocytes
from a rat pretreated with the oral -blocker propranolol. Pre-
treatment with propranolol reduced the apparent level of base-
line phosphorylation, as densitometric analysis indicated 1.5
and 3 times greater PKA-induced phosphorylation of TnI and
MyBP-C, respectively.
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address whether the greater absolute power output resulted
from greater force-generating capacity or faster loaded short-
ening, force-velocity and power-load curves were normalized
to isometric force before and after PKA treatment (Figure 4).
After PKA treatment, the velocity of myocyte shortening was
greater at relative loads 70% isometric force, suggesting
faster crossbridge cycling after phosphorylation of MyBP-C
and TnI. The bottom panel of Figure 4 shows that normalized
power output was greater at nearly all relative loads, and peak
normalized power output was 20% greater (0.0770.006
versus 0.0920.014 P/Po · ML · s1) after PKA treatment.
These results suggest that phosphorylation of myofibrillar
proteins by PKA increases absolute power output of single
myocytes by both increasing force-generating capacity, such
that a given absolute load is a lesser fraction of isometric
force, and by increasing loaded shortening rates at most
relative loads, which likely results from faster rates of
crossbridge cycling under load.
Because Ca2 activation of myofilaments does not likely
reach maximum in vivo, we also examined the effects of PKA
on force, velocity, and power during half-maximal Ca2
activations. These effects are summarized in Table 3. After
PKA treatment, Ca2 sensitivity of force was reduced such
that the pCa solution that yielded half-maximal activation
shifted from 5.640.08 before PKA treatment to 5.530.08
after PKA treatment (P0.001, paired t test). PKA treatment
also shifted normalized force-velocity and power-load curves
upward during half-maximal Ca2 activations (Figure 5).
Interestingly, during half-maximal Ca2 activation, the PKA-
induced increase in peak normalized power output was
greater than that observed during maximal Ca2 activations
(33% versus 19%). Also, during half-maximal Ca2 activa-
tions, normalized power output was greater at all relative
loads and, in fact, the difference in power output before and
after PKA treatment increased as relative load increased until
finally converging at isometric force, where there was no
shortening. Overall, these results imply that loaded cross-
bridge cycling is faster after phosphorylation of MyBP-C and
TnI during half-maximal Ca2 activation, and this effect is
relatively greater than that observed during maximal Ca2
activation.
A final series of control experiments was performed by
incubating myocytes in PKA plus PKI. These four myocytes
had preparation lengths of 15025 m and widths of 193
m. After incubation of the myocytes in PKAPKI, there
was no increase in force during maximal Ca2 activation
(force before PKAPKI8.81.6 N; force after
PKAPKI8.12.1 N [P0.10]). Additionally, force-
velocity and power-load curves were similar before and after
treatment with PKAPKI during half-maximal Ca2 activa-
tions. Peak normalized power output was 0.0730.019 be-
fore and 0.0670.014 P/Po · ML · s1 after PKAPKI,
respectively (P0.21). These results are consistent with the
conclusion that changes in skinned myocyte contractility after
PKA treatment arise from PKA-induced phosphorylation of
MyBP-C and/or TnI.
Discussion
We examined the effects of PKA-induced phosphorylation
of cardiac myofibrillar proteins on isometric and isotonic
contractions of single skinned cardiac myocytes. Maximal
Ca2-activated force, peak absolute power, and peak nor-
malized power were all significantly greater after PKA
treatment. Because peak power was greater after PKA
treatment even when normalized for changes in force, we
conclude that PKA increased absolute peak power, in part,
by speeding loaded crossbridge cycling rates. These results
Figure 5. Cumulative force-velocity and normalized power-load
curves obtained during half-maximal Ca2 activations of cardiac
myocyte preparations before and after PKA treatment (n9).
Peak normalized power output increased 30% after PKA
treatment.
Figure 4. Cumulative force-velocity and power-load curves nor-
malized for isometric force before and after PKA treatment of
cardiac myocyte preparations (n5). These curves were
obtained from preparations that were maximally Ca2 activated.
Peak normalized power output increased 20% after PKA
treatment.
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provide evidence that the enhancement of myocardial
performance by -adrenergic stimulation may be mediated
partly through effects of phosphorylation of myofibrillar
proteins to accelerate the transition steps in the crossbridge
cycle that limit power output.
Effects of -Adrenergic Stimulation on
Myofilament Function
-Adrenergic stimulation of intact hearts or PKA treatment of
skinned myocardium phosphorylates two myofibrillar pro-
teins, MyBP-C and TnI, in mammalian hearts.3 A variety of
experimental approaches have examined whether and how
PKA-induced phosphorylation of TnI and MyBP-C alters
cardiac myofilament function. These studies have for the
most part addressed the effects of phosphorylation on isomet-
ric contractile properties and unloaded shortening velocities.
Regarding isometric parameters, both -adrenergic receptor
stimulation of intact myocardium4 and PKA treatment of
skinned myocardium9,11–13,19,20 have been reported to signif-
icantly reduce the Ca2 sensitivity of myofilament function.
This effect appears to be due to phosphorylation of two serine
residues in the N-terminal region of cardiac TnI,21 which
lowers the affinity of TnC for Ca2.19,22 It has been suggested
that such a reduction in Ca2 sensitivity of myofilament
function may work to speed isovolumic relaxation of the
heart during -adrenergic stimulation, which would allow
adequate filling of the ventricles during diastole.20 Aside from
reducing Ca2 binding affinity of TnC, PKA-induced phos-
phorylation of myofibrillar proteins could also influence
myocardial function by altering crossbridge cycling rates.
Consistent with this idea, experiments on intact rabbit and rat
papillary muscles demonstrated that the frequency of mini-
mum stiffness was increased after -adrenergic stimulation
during Ba2 contractures.7,8 These results indicated that the
-adrenergic–induced acceleration of isometric crossbridge
cycling rates occurs independently of any changes in cytoso-
lic Ca2 handling and, thus, were the result of phosphoryla-
tion of TnI and/or MyBP-C. Consistent with these results,
isometric relaxation rates after rapid chelation of Ca2 were
accelerated after PKA treatment of skinned porcine23 and
murine24 myocardial preparations. These results were also
interpreted as an acceleration of isometric crossbridge cycling
rates in response to phosphorylation of myofibrillar proteins.
In contrast, however, de Tombe and Steinen9 found no
change in isometric myofibrillar ATPase activity during
maximal Ca2-activated isometric contractions after PKA
treatment of skinned rat trabeculae, which implies no change
in Ca2-activated isometric crossbridge cycling rates. Addi-
tional studies have investigated the effects of -adrenergic
stimulation on unloaded muscle shortening. de Tombe and ter
Keurs10 showed that unloaded sarcomere shortening in-
creased as a sigmoid function of isoproterenol concentration
in intact rat trabeculae preparations. However, isoproterenol
did not increase unloaded shortening at optimal [Ca2]o,
which implies that -adrenergic stimulation only speeds
crossbridge cycling rates secondary to its effects on Ca2
handling in these preparations. Other studies have similarly
reported no change in unloaded shortening rates in either rat
skinned trabeculae preparations11 or rat skinned cardiac
myocyte preparations12 after PKA treatment. Because mean
strain on crossbridges is likely to be lower during unloaded
contractions compared with isometric contractions, these
results have been reconciled with previous results from
isometric Ba2 contractures experiments by suggesting that
-adrenergic stimulation alters crossbridge cycling rates in a
strain-dependent manner. However, Strang et al13 observed
that both isoproterenol treatment of intact myocytes before
skinning and PKA treatment of skinned myocytes caused a
40% increase in unloaded shortening rates. A similar
increase in unloaded shortening rates was reported after PKA
treatment of single skinned mouse cardiac myocytes.14
Overall, it is clear that PKA has elicited highly variable
experimental responses on cardiac myofilament function, and
these differences are difficult to reconcile. Although the exact
reasons for these differences are unknown, they certainly may
arise from differences in types of animals or in myocardial
preparations (eg, multicellular or single cell), variations in
contractile protein isoform expression, and/or variable levels
of baseline phosphorylation of myofibrillar proteins. Regard-
ing the latter possibility, we attempted to minimize MyBP-C
and TnI phosphorylation levels before PKA treatment by
treating animals with the -blocker propranolol well in
advance of euthanasia. Based on autoradiography, this ap-
peared to reduce baseline phosphorylation of MyBP-C and
TnI, as indicated by greater PKA-induced phosphorylation of
MyBP-C and TnI from propranolol-treated animals (Figure
2). This may explain the rather robust changes in myocyte
shortening rates and perhaps the significant increase in
maximal Ca2-activated isometric force observed in this
study after PKA treatment. Another possibility for the PKA-
induced changes observed in this study but not in others is
that myocytes were obtained from young (2- to 3-month-old)
male rats that expressed predominantly V1 myosin
isozyme,25,26 which has been found to be more responsive to
-adrenergic stimulation than preparations containing V3
myosin.8,27,28
As mentioned above, the studies that have investigated
-adrenergic stimulation on cardiac myofilament function
have for the most part focused on one or both extremes of the
force-velocity relationship (ie, isometric or unloaded contrac-
tions). Only a few studies have investigated whether
-adrenergic stimulation affects muscle shortening rates over
a broad range of loads. Chiu et al29 measured the effect of
isoproterenol on force-velocity properties of intact rabbit
papillary muscles. Isoproterenol increased both shortening
velocity and power output at all loads, even when power was
normalized for the increase in twitch force associated with
-adrenergic stimulation. However, one limitation of this
study is that, because Ca2 activation levels increase after
-adrenergic stimulation, it is impossible to discern the
proportion of the increase that resulted from the elevated
amount of activator Ca217 versus a direct effect of phospho-
proteins on crossbridge cycling rates. The increased power
could have arisen entirely from increased [Ca2]i, especially
given the tight Ca2 dependence of myocyte loaded shorten-
ing rates.17 Furthermore, de Tombe and ter Keurs10 concluded
that increased [Ca2]i after isoproterenol alone sped unloaded
sarcomere shortening of intact trabecular preparations, given
1188 Circulation Research December 7/21, 2001
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that isoproterenol had no effect on unloaded shortening rates
during optimal [Ca2]o activations. We attempted to dissect
out a phosphoprotein effect from a Ca2 effect per se by
utilizing skinned cardiac myocyte preparations, which al-
lowed control of the free Ca2 concentration bathing the
myocyte and activating the thin filaments. Thus, our prepa-
ration allowed us to examine the direct effects of PKA on
crossbridge cycling kinetics during loaded contractions, in-
dependently of PKA-mediated increases in myoplasmic Ca2.
The finding that force-velocity relationships were shifted to
higher velocities in skinned myocyte preparations after PKA
treatment suggests that the previously observed -adrener-
gic–induced shifts to faster velocities at similar relative loads
in intact cardiac muscle preparations arose, at least in part,
from a direct effect of phosphoproteins to speed crossbridge
cycling rates. Interestingly, in our study, PKA increased peak
normalized power output to a greater extent during submaxi-
mal Ca2 activations than during maximal Ca2 activations.
This resulted from a greater fractional increase in loaded
shortening velocity at Fopt (the relative load at which power
was optimal) during submaximal Ca2 activations. The exact
reasons for this finding are unknown but it suggests that the
crossbridge transition(s) that limits peak power output is
modulated by phosphoproteins in a Ca2-dependent manner.
Structural Changes in TnI and MyBP-C After
PKA-Induced Phosphorylation
Potential mechanisms for faster myocyte loaded shortening
rates after PKA-induced phosphorylation may involve struc-
tural changes in either TnI or MyBP-C. As mentioned above,
cardiac TnI contains serial serine residues at positions 22 and
23 that are substrates for PKA. Phosphorylation of these
residues causes folding of TnI at its N-terminal extension.30
This conformational change weakens the cooperative binding
of TnI to actin-tropomyosin31 and reduces the affinity of TnI
for TnC, especially in the presence of Ca2.32,33 Because the
interaction between TnI and TnC increases Ca2 binding,
reduced TnI/TnC binding lowers the affinity of TnC for
Ca2.19,22 This reduction in Ca2 binding to TnC after TnI
phosphorylation likely underlies the reduced Ca2 sensitivity
previously discussed. Moreover, recent evidence from studies
in transgenic mice implies that phosphorylation of the two
N-terminal TnI residues is necessary to speed maximal
velocity of shortening,14 isometric crossbridge kinetics, and
myofibrillar relaxation rates.24 Thus, it is conceivable that
faster crossbridge cycling rates after phosphorylation of TnI
may be solely responsible for the increased power observed
in this study. Alternatively, the cardiac isoform of MyBP-C is
also phosphorylated by PKA after -adrenergic stimulation.
MyBP-C is tris-phosphorylated by PKA at a conserved
N-terminal domain known as the MyBP-C motif.34 Phosphor-
ylation of MyBP-C has been reported to relieve the binding of
the MyBP-C to the S2 portion of myosin,35 which may allow
greater crossbridge extension from the thick filament and
alter crossbridge orientation.28 These alterations in cross-
bridge constraints after MyBP-C phosphorylation may allow
additional recruitment of crossbridges to bind actin and/or
alter crossbridge cycling rates. Future studies are needed to
determine precisely which phosphorylation sites on TnI,
MyBP-C, or both are most important in conferring increased
power generating capacity in cardiac myocytes.
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